Malik Y. Kahook

The Slater Family Endowed Chair in Ophthalmology, Vice Chair of Translational Research, Chief of the Glaucoma Service, and Co-Director of the Glaucoma Fellowship, Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, Colorado, USA

What industry trends are catching your attention right now?

The most exciting thing in the field of glaucoma as I write is extended drug delivery. We have had a few years of access to Durysta (AbbVie) now and we better understand the pros and cons of that platform. Now we have iDose (Glaukos) entering the market with a different value proposition and extended duration of delivery. I’m excited to be working with SpyGlass Pharma, which also has a unique value proposition in both mode of delivery as well as extended multi-year duration of action. I feel that drug delivery is going to be a major part of changing the treatment paradigm for glaucoma and other chronic ophthalmic diseases for years to come.

What is an interesting or little-known fact about you?

I am an avid hiker and recently summited Mount Fuji with a couple of close friends.

Make a bold prediction for the future of ophthalmology.

Humanoid robots will be a regular part of the patient care team (in the clinic and operating room) within the next 10 years.